Prescribing DUAKLIR

Prescription pad with DUAKLIR PRESSAIR 400 mcg/12 mcg twice a day (BID)

Dosing for Duaklir

Duaklir® Pressair® is prescribed twice-daily for improvement in lung function day and night. DUAKLIR (aclidinium bromide/formoterol fumarate) inhalation powder 400 mcg/12 mcg is indicated for the maintenance treatment of patients with COPD.2

Up to 80% of COPD Patients Use Their Device Incorrectly13

Clear Reassurance of Dose Delivery

PRESSAIR is the only preloaded, dry powder inhaler that reassures your patients through 2 ways* that they have taken their dose correctly.2

 

A “click” will sound when you've inhaled your medicine correctly

The color-controlled window changes from GREEN to RED when you've successfully inhaled the full dose

Duaklir Pressair is a simple, easy-to-use device:

Preloaded and ready to use
PRESSAIR has a built-in dose indicator with a locking mechanism to ensure patients know when their medication is finished
No dosage adjustments necessary for elderly or renally impaired patients

DUAKLIR does not replace the use of rescue inhalers.

*Feedback mechanisms consist of visual cues (color-controlled window) and an audible "click."

DUAKLIR PRESSAIR Device

A DUAKLIR Dose Is Delivered in 3 Simple Steps2

PRESSAIR In Hand, Finger Pressing Down on Orange Button

1 READY before inhalation

  • Remove cap and hold upright.
  • PRESS and RELEASE the orange button.
  • Check the color-controlled window. GREEN means the medicine is READY for inhalation.
  • Before you put the inhaler in your mouth, breathe out completely. Do not breathe out into the inhaler. Then place your lips tightly around the mouthpiece.
PRESSAIR held up to mouth, medicine entering mouth

2 DURING inhalation

  • TAKE A STRONG, DEEP BREATH IN.
  • A "CLICK" will sound during inhalation when the inhaler is used correctly.
  • Keep breathing in as long as possible after you hear the "CLICK." 
Straight-on view of PRESSAIR

3 CONFIRM after inhalation

  • Remove the inhaler from your mouth and hold your breath for as long as possible, and then slowly breathe out, away from the inhaler.
  • CONFIRM the color-controlled window has turned from green to RED to ensure the full dose has been inhaled correctly.

If you would like to print or keep a copy of the instructions, please select the "download instructions" button below.

Download Instructions

How to Use DUAKLIR 

Watch this video on using DUAKLIR to help your patients inhale their dose correctly.

Indication and Usage

DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma and increases the risk of asthma-related death. When LABA are used in fixed-dose combinations with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone.
  • DUAKLIR PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or formoterol fumarate or any component of the product
  • DUAKLIR PRESSAIR is not indicated for the treatment of acute episodes of bronchospasm (i.e. rescue therapy)
  • Do not initiate DUAKLIR PRESSAIR with an additional medicine containing a LABA because of risk of overdose or in acutely deteriorating COPD
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of DUAKLIR PRESSAIR. Additionally, inhaled medicines, including DUAKLIR PRESSAIR, may cause paradoxical bronchospasm which may be life threatening. If any of these occurs, immediate treatment with a short acting bronchodilator should be initiated and treatment with DUAKLIR PRESSAIR should be stopped and alternative therapy initiated
  • DUAKLIR PRESSAIR should be used with caution in patients with cardiovascular and convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, hypokalemia, hyperglycemia, narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of acute narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop
  • The most common adverse reactions (≥3% incidence and more common than placebo) were upper respiratory tract infection (8.9% vs 6.3%), headache (6.3% vs 5.1%), and back pain (3.8% vs 3.4%) for DUAKLIR PRESSAIR vs placebo, respectively. Other adverse reactions reported in clinical studies (>1% but less than 3% and more common than placebo) with DUAKLIR PRESSAIR were cough, sinusitis, influenza, tooth abscess, insomnia, dizziness, dry mouth, oropharyngeal pain, muscle spasm, musculoskeletal pain, arthralgia, pain in extremity, urinary tract infection, and increased blood creatine phosphokinase

Medical Information

For answers to your medical questions about DUAKLIR PRESSAIR, please contact Circassia Medical Information at medinfo.us@circassia.com.

Please also see the full Prescribing Information, including Patient Information.

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate,
  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as

Indication and Usage

DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma and increases the risk of asthma-related death. When LABA are used in fixed-dose combinations with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone.
  • DUAKLIR PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or formoterol fumarate or any component of the product
  • DUAKLIR PRESSAIR is not indicated for the treatment of acute episodes of bronchospasm (i.e. rescue therapy)
  • Do not initiate DUAKLIR PRESSAIR with an additional medicine containing a LABA because of risk of overdose or in acutely deteriorating COPD
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of DUAKLIR PRESSAIR. Additionally, inhaled medicines, including DUAKLIR PRESSAIR, may cause paradoxical bronchospasm which may be life threatening. If any of these occurs, immediate treatment with a short acting bronchodilator should be initiated and treatment with DUAKLIR PRESSAIR should be stopped and alternative therapy initiated
  • DUAKLIR PRESSAIR should be used with caution in patients with cardiovascular and convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, hypokalemia, hyperglycemia, narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of acute narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop
  • The most common adverse reactions (≥3% incidence and more common than placebo) were upper respiratory tract infection (8.9% vs 6.3%), headache (6.3% vs 5.1%), and back pain (3.8% vs 3.4%) for DUAKLIR PRESSAIR vs placebo, respectively. Other adverse reactions reported in clinical studies (>1% but less than 3% and more common than placebo) with DUAKLIR PRESSAIR were cough, sinusitis, influenza, tooth abscess, insomnia, dizziness, dry mouth, oropharyngeal pain, muscle spasm, musculoskeletal pain, arthralgia, pain in extremity, urinary tract infection, and increased blood creatine phosphokinase

Medical Information

For answers to your medical questions about DUAKLIR PRESSAIR, please contact Circassia Medical Information at medinfo.us@circassia.com.

Please also see the full Prescribing Information, including Patient Information.

REFERENCES: 1. Loveridge B, et al. Am Rev Respir Dis. 1986;134(5):930-934. 2. Duaklir® Pressair® (aclidinium bromide/formoterol fumarate inhalation powder)[prescribing information]. Morrisville, NC: Circassia Pharmaceuticals Inc; 2019. 3. Sethi S, et al. International Journal of COPD. 2019;14:667-682. 4. Data on file, Circassia. 5. Jones PW, et al. Respir Med. 1991;85(suppl B):25-31. 6. D'Urzo AD, et al. Respir Res. 2014;15:123. 7. Miravitlles M, et al. Respir Res. 2014;15:122. 8. Balachandran J, et al. Am J Respir Grit Care Med. 2013;188:5-6. 9. Singh D, et al. BMC Pulmonary Medicine. 10. Cote CG, et al. Chest. 2008;134:104001. 11. Wise RA, et al. JAMA. 2019;321(17):1693-1701. 12. Tudorza® Pressair® (aclidinium bromide inhalation powder) [prescribing information]. Morrisville, NC: Circassia Pharmaceuticals Inc; 2019. 13. Ocakli B, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:2941-2947. 14. Centers for Disease Control and Prevention. Chronic Obstructive Pulmonary Disease Among Adults – United States, 2011. MMWR. Nov 2012;61(46);938-943. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6146a2.htm?s_cid=mm6146a2_w. Accessed April 7, 2016. 15. Centers for Disease Control and Prevention. Deaths: Leading Causes for 2017. National Vital Statistics Reports. 2019;68(6). https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_06-508.pdf. Published June 24, 2019. Accessed August 19, 2019. 16. National Heart, Lung, and Blood Institute (NHLBI). Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. http://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf. Published February 2012. Accessed April 7, 2016. 17. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Updated November 2018. Accessed July 16, 2019. 18. Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD Surveillance–United States, 1999-2011. Chest. 2013;144(1):284-305. 19. Chronic Obstructive Pulmonary Disease (COPD) Includes: Chronic Bronchitis and Emphysema. National Center for Health Statistics website. https://www.cdc.gov/nchs/fastats/copd.htm. Updated May 3, 2017. Accessed July 16, 2019. 20. American Lung Association. What Causes COPD. http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/symptoms-causes-risk-factors/what-causes-copd.html. Published 2016. Accessed April 7, 2016. 21. World Health Organization. Causes of COPD. http://www.who.int/respiratory/copd/causes/en/#. Accessed April 7, 2016.